| Trial ID: | L2058 |
| Source ID: | NCT02777073
|
| Associated Drug: |
Victoza
|
| Title: |
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
|
| Acronym: |
1974
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02777073/results
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: Victoza|DRUG: Placebo|DRUG: Dapagliflozin 10mg Tab
|
| Outcome Measures: |
Primary: Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin, To compare levels of ketone bodies beta-hydroxybutyrate in plasma following a single dose treatment of either liraglutide 1.8mg,dapagliflozin 10mg or placebo in insulinopenic state., 8 hours | Secondary: Change in Glucagon Levels., This secondary endpoint compares change in glucagon concentrations (in pg/ml) from baseline at 8 hours following liraglutide and dapagliflozin compared to placebo, 8 hours|Change in Free Fatty Acid (FFA) Concentrations, This secondary endpoint compares the change in FFA concentrations (mM) from baseline at 8 hours following liraglutide and dapagliflozin compared to placebo, 8 hours|Change in Ghrelin Concentrations, This secondary endpoint compares the change in ghrelin concentrations (pg/ml) from baseline at 8 hours following liraglutide and dapagliflozin compared to placebo, 8 Hours
|
| Sponsor/Collaborators: |
Sponsor: University at Buffalo
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
43
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-03-01
|
| Completion Date: |
2016-12-31
|
| Results First Posted: |
2024-02-29
|
| Last Update Posted: |
2024-02-29
|
| Locations: |
ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, 14215, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02777073
|
